Fycompa (perampanel) is a small molecule pharmaceutical. Perampanel was first approved as Fycompa on 2012-07-23. It is used to treat partial epilepsies, seizures, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat partial epilepsies. Fycompa's patents are valid until 2026-07-01 (FDA).
|Indication||partial epilepsies, seizures, tonic-clonic epilepsy|
|Drug Class||Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors): antagonists|